Cardiovascular MRI evidence of reduced systolic function and reduced LV mass in rheumatoid arthritis: impact of disease phenotype

L. A. Bissell1,2 · B. Erhayiem3 · E. M. A. Hensor1,2 · G. Fent3 · A. Burska1,2 · A. K. McDiarmid3 · P. P. Swoboda3 · H. Donica4 · S. Plein3 · M. H. Buch1,2 · J. P. Greenwood3 · J. Andrews1,2

Received: 11 March 2019 / Accepted: 12 October 2019 / Published online: 8 February 2020
© The Author(s) 2020

Abstract
The accelerated risk of cardiovascular disease (CVD) in Rheumatoid Arthritis (RA) requires further study of the underlying pathophysiology and determination of the at-risk RA phenotype. Our objectives were to describe the cardiac structure and function and arterial stiffness, and association with disease phenotype in patients with established RA, in comparison to healthy controls, as measured by cardiovascular magnetic resonance imaging (CMR). 76 patients with established RA and no history of CVD/diabetes mellitus were assessed for RA and cardiovascular profile and underwent a non-contrast 3T-CMR, and compared to 26 healthy controls. A univariable analysis and multivariable linear regression model determined associations between baseline variables and CMR-measures. Ten-year cardiovascular risk scores were increased in RA compared with controls. Adjusting for age, sex and traditional cardiovascular risk factors, patients with RA had reduced left ventricular ejection fraction (mean difference − 2.86% (− 5.17, − 0.55) p = 0.016), reduced absolute values of mid systolic strain rate (p < 0.001) and lower late/active diastolic strain rate (p < 0.001) compared to controls. There was evidence of reduced LV mass index (LVMI) (− 4.56 g/m² (− 8.92, − 0.20), p = 0.041). CMR-measures predominantly associated with traditional cardiovascular risk factors; male sex and systolic blood pressure independently with increasing LVMI. Patients with established RA and no history of CVD have evidence of reduced LV systolic function and LVMI after adjustment for traditional cardiovascular risk factors; the latter suggesting cardiac pathology other than atherosclerosis in RA. Traditional cardiovascular risk factors, rather than RA disease phenotype, appear to be key determinants of subclinical CVD in RA potentially warranting more effective cardiovascular risk reduction programs.

Keywords Rheumatoid arthritis · Cardiovascular disease · Cardiovascular MRI

L. A. Bissell
l.a.bissell@leeds.ac.uk

B. Erhayiem
B.Erhayiem@leeds.ac.uk

E. M. A. Hensor
e.m.a.hensor@leeds.ac.uk

G. Fent
G.Fent@leeds.ac.uk

A. Burska
A.N.Burska@leeds.ac.uk

A. K. McDiarmid
A.K.McDiarmid@leeds.ac.uk

P. P. Swoboda
P.Swoboda@leeds.ac.uk

H. Donica
donicahelena@gmail.com

S. Plein
S.Plein@leeds.ac.uk

M. H. Buch
m.buch@leeds.ac.uk

J. P. Greenwood
j.greenwood@leeds.ac.uk

1 Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

2 NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK

3 Multidisciplinary Cardiovascular Research Centre & The Division of Biomedical Imaging, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK

4 Medical University of Lublin, Lublin, Poland
Introduction

Rheumatoid arthritis (RA) is associated with an accelerated risk of cardiovascular disease (CVD), with both traditional cardiovascular risk factors and systemic inflammation playing a role [1]. To improve on the European league against rheumatism (EULAR) recommendations for reducing CVD in RA [2], there is a need for greater understanding of the underlying pathophysiology and determination of the RA phenotype most at risk of CVD.

Cardiovascular magnetic resonance (CMR) imaging provides highly reproducible quantitative assessment of the heart and cardiovascular system, with high diagnostic accuracy for ischaemic heart disease (IHD) [3]. CMR is increasingly used as a research tool in patients with RA, detecting the presence of subclinical disease in populations free of clinical CVD [4–8]. The largest CMR study in RA (n = 75, some with diabetes) reported a 4.4% reduction in LV ejection fraction (LVEF), but interestingly also a 15% reduction in LV mass index (LVMI) in those with RA [9]. A preliminary CMR report of 66 patients with treatment-naive early RA also demonstrated a reduced LVMI [10]. Both of these CMR studies stand in contrast to echocardiographic data [11] and smaller CMR studies in RA [8, 12] reporting no difference or increase in LV mass. This is of pathophysiological interest given the occurrence of heart failure in RA is not fully attributable to traditional cardiovascular risk factors or the presence of IHD [13].

This exploratory study describes cardiac structure and function and arterial stiffness in patients with established RA free of known CVD and diabetes mellitus, in comparison to healthy controls, as measured by CMR. The study also describes the association of any cardiovascular abnormalities with RA disease phenotype, to provide insight into the patients most at risk of CVD.

Methods

Consecutive patients with RA attending rheumatology clinics between January 2011 and September 2014 at the Leeds Teaching Hospitals NHS Trust were considered for this study. Patients were eligible if between 18 and 80 years old, met 1987 ACR criteria [14], had disease for 5 years or more and no history of CVD or diabetes mellitus. Healthy controls, with no history of RA or osteoarthritis affecting their mobility, were mainly identified by asking patients with RA to ‘bring a friend’. This study had full ethical approval; REC 09/H1307/98 and REC 10/H1307/103, NRES Leeds West ethics committee. Following written informed consent obtained according to the Declaration of Helsinki, study participants were invited to undergo a cardiovascular clinical assessment, fasting blood collection and CMR.

Clinical assessment

A clinical evaluation recorded demographic data, traditional cardiovascular risk factors and for patients with RA, disease phenotype including 3-variable DAS28-C-reactive protein (CRP) [15] and Health Assessment Questionnaire-Disease Index [16]. Fasting lipid profile and glucose were measured, and rheumatoid factor (RF), anti-cyclic citrullinated peptide antibody (ACPA), CRP, erythrocyte sedimentation rate in those with RA. Additional blood samples were processed and stored (some at − 30 °C and some at − 80 °C) for later analysis at the Department of Biochemical Diagnostics, Medical University of Lublin, Poland; glucose (using biochemical analyser Cobas INTEGRA 400); N-terminal pro-brain natriuretic peptide (NT-proBNP) (using Cobas 6000 (immunochemistry module Cobas e601)) and insulin (using COBAS e 411 (Roche Diagnostics GmbH, Mannheim, Germany) and appropriate Roche Diagnostics assays). Homeostasis model assessment-estimated insulin resistance (HOMA-IR) was then calculated (fasting insulin (μU/ml) × fasting glucose (mg/dl)/405) [17].

CMR imaging

The CMR study was performed on a 3T Philips Achieva system TX equipped with a 32-channel coil. Low resolution survey, reference scans and localisers determined the cardiac short axis, vertical long axis and horizontal long axis with cine imaging (balanced steady state free precession (SSFP) acquisition, see Fig. 1). LV dimensions and function were obtained from cines covering the entire heart in the LV short axis [18, 19] (balanced SSFP, multiphase, contiguous slices, voxel size 1.2 × 1.2 × 10 mm³, 50 cardiac phases).

For aortic distensibility, high temporal resolution sagittal-oblique and transverse cines were acquired to measure the diameter and area of the ascending aorta, descending aorta and aortic arch at the level of the main pulmonary artery [20]. Blood pressure was recorded immediately prior to image acquisition. Aortic pulse wave velocity (PWV) was assessed using identical geometry planning with retrospectively gated, through-plane, phase-contrast velocity encoded images (breath-hold, single slice, 10 mm thick, 50 phases, VENC 200 cm/s).

Tissue tagging for strain analysis and diastology were generated from the basal, mid and apical LV using the 3-of 5′ approach [21] (spatial modulation of magnetization pulse sequence, spatial resolution 1.51 × 1.57 × 10 mm³, tag separation 7 mm, ≥ 18 phases, typical TR/TE 5.8/3.5 ms, flip angle 10°).
Native T1 mapping was acquired with a single breath-hold mid-slice in the LV short axis using an electrocardiogram-triggered modified Look-Locker inversion method to acquire 11 images (3-3-5 acquisition with 3 × R–R interval recovery epochs, voxel size 1.7 × 2.14 × 10 mm³ Trigger delay at end-diastole, flip angle 35°, FOV 320–420 mm) [22, 23].

**Data analysis**

Image analysis was performed off-line blinded to patient characteristics using CMR42 (CVI42 v4.1.3, Circle Cardiovascular Imaging Inc., Calgary, Canada) and in accordance to recognised reporting standards [24]. LV dimensions and function (excluding papillary muscles) were calculated using standard criteria to delineate cardiac borders [24]. Aortic cross-sectional measurements were made by manual planimetry of the endovascular-blood pool interface, at maximal and minimal distension of the aorta. Aortic distensibility (strain/(pulse pressure (mmHg)) × 1000) [25], and aortic PWV (distance between area of ascending aorta and area of descending aorta/transit time for wave to cover distance) [25, 26] were calculated. Analysis was performed using in-house software (PMI 0.4) based on IDL 6.4 (ITT Visual Information Systems, Boulder, CO, USA) [27].

Strain analysis and LV torsion from the tagging series was derived using the open source software Osirix inTag (http://www.osirix-viewer.com). LV twist was calculated by subtracting the basal from apical rotation [28]. LV torsion takes the heart radius and length into account, describing it as the circumferential-longitudinal shear angle making the measurement comparable between hearts of different sizes and is related to myocardial fibre orientation [29]; calculated by peak twist × (apical radius + basal radius))/(2 × apex to base length).

Native myocardial T1 was measured from a desired region of interest (ROI) in the mid-ventricular wall [30]. The ROI was manually motion corrected as required from source images and care taken to avoid partial-volume effects from neighbouring tissue or blood pool.

**Statistical analysis**

The statistical packages SPSS (IBM SPSS Statistics 22) and Stata/IC 13.1 were used. Following a descriptive analysis, independent t-tests determined unadjusted differences between patients with RA and controls. Linear regression
Results

Ninety-five consecutive patients with RA were recruited; 76 of these underwent CMR. Thirty healthy controls were recruited and 26 of these underwent CMR. Reasons for not having CMR performed included claustrophobia (RA n = 6), difficulty in contacting patient for CMR (RA n = 7, controls n = 3) or patient changing their mind (RA n = 3, controls n = 3). Non-MR compatible implant (RA n = 1), patient too large for scanner (RA n = 1) and incomplete study data retrieved (n = 1).

Study participant characteristics

Of those who underwent a CMR scan, Tables 1 and 2 outline the demographic, cardiovascular risk profile and RA disease-specific features. The mean age (standard deviation, SD) of patients with RA was 60 (9.2) years, 74% were female and 95% white. Median (interquartile range, IQR) disease duration was 16.5 (10.7, 25.7) years, 90% were seropositive for RF or ACPA and 78% had erosive disease. Patients overall were in remission; median (IQR) 3 variable-DAS28 2.39 (1.15, 3.36). A significant proportion had cardiovascular risk factors, including 33% with hypertension. The control group were younger (mean (SD) age 51.8 (11.8) years) with fewer (54%) females and fewer cardiovascular risk factors.

In patients with RA, TC/HDL-C ratio was not associated with C-reactive protein, 3-variable DAS28, ACPA or RA disease duration (data not shown); with similar findings excluding patients on a statin (n = 12). There were weak, positive associations between NT-proBNP and both age and RA disease duration (r = 0.325, p = 0.006, and r = 0.278, p = 0.019 respectively). There were also weak, positive associations between HOMA-IR and both body mass index and waist/hip circumference ratio (r = 0.240, p = 0.044 and r = 0.368, p = 0.002 respectively).

Cardiovascular magnetic resonance imaging

Differences between patients and controls

The CMR results are shown in Table 3. No pericardial effusions were noted. No significant valvular pathology or cardiac masses or features of cardiomyopathy were detected, although flow imaging and post-contrast imaging were not performed. Patients with RA demonstrated a reduction in absolute values for mid systolic strain rate (mid S’) reducing further in the analysis adjusted for age, sex and cardiovascular risk factors (0.227 (0.104, 0.349), p < 0.001). They also demonstrated a reduction in LVEF (mean (SD) in RA 59.1 (4.6) vs. 59.7 (4.8) % in controls; borderline significant in the adjusted analysis (mean difference = 2.858 (−5.167, −0.550) %, p = 0.016). Although early diastolic strain rate was similar across the groups, active/late diastolic strain rate was reduced in those with RA in the adjusted analysis (− 0.45 (−0.67, −0.23), p < 0.001).

LVM1 was reduced in patients with RA (mean (SD) 36.35 (10.52) vs. 44.06 (14.49)g/m2 in controls, p=0.005), and when adjusted for age and sex, but not after further adjustment for cardiovascular risk factors, although the difference remained substantive (mean difference (95% CI) = −4.56 (−8.92, −0.199) p = 0.041).

Whilst aortic distensibility was lower in RA in the unadjusted analysis, there was no substantive/statistical difference in the adjusted analysis between the groups. The remaining differences were substantive but did not meet the revised threshold for statistical significance.
Association with RA disease phenotype and soluble cardiovascular biomarkers

LVEF and LVMI were analysed further given the differences seen between the groups and provision of information on structure/function. A univariate analysis (Table 4) in those with RA found that male sex, systolic blood pressure (sysBP) and waist/hip circumference ratio were associated with increasing LVMI, with male sex and sysBP independently associated with LVMI in a multivariable linear regression analysis (MVA). Although no variables were associated with LVEF on univariate analysis (Table 5), male sex was associated with LVEF in a MVA. No RA-specific features were associated with CMR-outcomes.

Discussion

In a population of established RA free of CVD and diabetes mellitus, combining clinical assessment with measurements of soluble biomarkers of CVD and CMR, this study reports a reduction in systolic function (LVEF, peak mid systolic strain rate), early/mid diastolic strain rate and LVMI after controlling for age, sex and traditional cardiovascular risk factors, and the association of surrogate measures of CVD...
with traditional cardiovascular risk factors rather than RA disease-specific features.

The only similar sized CMR study in RA (n = 75) by Giles et al. also reported a 4.4% reduction in LVEF and 15% reduction in LVMI in the adjusted mean values in patients free of known CVD compared to controls (n = 225), after adjustment for blood pressure, heart rate, HDL-C, triglycerides, habitual exercise and coronary calcium score [9]. Although age, smoking habits and statin use in their study were comparable to our study, there were fewer females (52%), fewer white (88%), greater burden of hypertension (55%) and importantly, inclusion of patients with diabetes (4%). Their patients with RA may have been subjected to a smaller burden of inflammation than in our study (shorter disease duration and fewer on biological disease modifying anti-rheumatic drugs (49%)) however they were not in remission (mean DAS28 3.51).

Our study demonstrates similar results in patients free of diabetes with a reduction in the adjusted mean values in LVEF of 5.11% (intercept 55.884, B − 2.858 (95% CI − 5.167, − 0.550) p = 0.016) and LVMI of 15.5% (intercept 29.456, B − 4.558 (95% CI − 8.917, − 0.199) p = 0.041) for patients with RA, who were overall in remission, i.e. CMR abnormalities despite no active RA disease.

Other CMR studies to date reporting LVEF have been inconsistent involving smaller cohorts [12] and shorter disease duration [8]. Although Ntusi et al. reported similar LVEF, they did determine reduced peak systolic circumferential strain and reduced diastolic strain rate in those with RA [8]. Similarly, smaller CMR studies have not described reduced LV mass [8, 12], although our research

### Table 2 Disease specific characteristics of patients with rheumatoid arthritis

| RA phenotype                                      | Data as expressed | RA patients |
|---------------------------------------------------|-------------------|-------------|
| Disease duration (years)                          | Median (IQR)      | 16.5 (10.7, 25.7) (range 4.2, 43.4) |
| Early morning stiffness (mins)                    | Median (IQR)      | 10 (10, 37.5) |
| History of orthopaedic joint surgery              | n %               | 21 (27.6) |
| Number of orthopaedic joint surgical episodes     | n %               | 10 (3.2)—1 episode |
|                                                    |                   | 3 (3.9)—2 episodes |
|                                                    |                   | 6 (7.9)—3 episodes |
|                                                    |                   | 2 (2.6)—4 episodes |
| Current use of oral prednisolone                  | n %               | 4 (5.3) |
| Current use of non-biological DMARD               | n %               | 62 (81.6) |
| Number of csDMARDs currently taking               | n %               | 48 (63.2) taking 1 |
|                                                    |                   | 8 (10.5) taking 2 |
|                                                    |                   | 8 (10.5) taking 3 |
| Number of previously tried csDMARDs               | Median (IQR)      | 2 (1.3) (range 0, 7) |
| Current use of biological DMARD                   | n %               | 51 (67.1) |
| Current TNFI users                                |                   | 22 (27.6) |
| Current Rituximab users                           |                   | 26 (34.2) |
| Current Tocilizumab users                         |                   | 3 (3.9) |
| Current Abatacept users                           |                   | 1 (1.3) |
| Number of treatment cycles in current RTX users   | Median (IQR)      | 4 (3, 5.25) (range 1, 9) |
| Number of previously tried biological DMARDs     | Median (IQR)      | 0 (0, 1) |
| Patient general health VAS                        | Median (IQR)      | 31 (15, 52) |
| 28-Tender joint count                             | Median (IQR)      | 2 (0, 6) |
| 28-Swollen joint count                            | Median (IQR)      | 0 (0, 1) |
| HAQ-DI                                            | Median (IQR)      | 1.44 (0.53, 2.00) |
| 3 variable DAS28CRP                               | Median (IQR)      | 2.39 (1.15, 3.36) |
| Erosions on hands/feet radiograph                 | n %               | 57/73 (78.1) |
| CRP (mg/L)                                        | Median (IQR)      | <5 (0, 7.8) |
| ESR (mm/h)                                        | Median (IQR)      | 14 (6, 27) |
| Rheumatoid factor positive (≥40iu/ml)             | n %               | 53 (69.7) |
| ACPA positive (≥10U/ml)                           | n %               | 61/75 (81.3) |

*ACPA* anti-citrullinated peptide antibody, *CRP* C-reactive protein, *csDMARDs* conventional synthetic DMARDs, DAS28CRP 28-joint disease activity score, DMARDs disease-modifying anti-rheumatic drugs, ESR erythrocyte sedimentation rate, HAQ-DI health assessment questionnaire-disability index, RTX rituximab, VAS visual assessment score
Echocardiography studies have repeatedly reported increased LV mass in patients with RA [32], and often no difference in LVEF [11, 33], although reduced LVEF has been associated with active disease [33]. CMR has now demonstrated greater reproducibility over echocardiography in determination of LV systolic function [34] and greater sensitivity to detect small differences in LVEF and LV mass [35], and is now widely accepted as the reference standard [34, 36].

Table 3 Cardiovascular magnetic resonance imaging measures in study participants

| Variable                        | RA patients n = 76 | Controls n = 26 | Unadjusted p value for difference | Mean difference (95% CI), p value adjusted for age and sex | Mean difference (95%), p value adjusted for age/sex/cardiovascular risk factors* |
|--------------------------------|-------------------|----------------|-----------------------------------|----------------------------------------------------------|--------------------------------------------------------------------------------|
| LV ejection fraction (%)       | 59.1 (4.6) (n = 74) | 59.7 (4.8) (n = 26) | 0.560                              | − 2.100 (− 4.268, 0.068), 0.057                         | − 2.858 (− 5.167, − 0.550) 0.016                                                 |
| LV EDV index (mL/m²)            | 79.09 (14.59) (n = 74) | 91.08 (24.32) (n = 26) | 0.024                              | − 5.15 (− 12.908, 1.878), 0.142                        | − 4.683 (− 12.275, 2.909) 0.224                                                 |
| LV ESV index (mL/m²)            | 32.45 (7.60) (n = 74) | 36.88 (12.00) (n = 26) | 0.032                              | − 0.545 (− 4.311, 3.222), 0.775                        | 1.187 (− 2.491, 4.865) 0.523                                                   |
| LV mass index (g/m²)           | 36.35 (10.52) (n = 74) | 44.06 (14.49) (n = 26) | **0.005**                         | − 5.421 (− 9.615, − 1.227), 0.012                      | − 5.458 (− 8.917, − 0.999) 0.041                                                 |
| LV mass/EDV (g/ml)             | 0.46 (0.10) (n = 74) | 0.48 (0.10) (n = 26) | 0.266                              | − 0.035 (− 0.075, 0.086), 0.142                      | − 0.033 (− 0.075, 0.010) 0.129                                                  |
| Stroke volume index (mL/m²)    | 46.29 (7.26) (n = 74) | 53.47 (11.20) (n = 26) | **0.005**                         | − 4.273 (− 7.998, − 0.548), 0.025                      | − 3.551 (− 7.516, 0.413) 0.078                                                  |
| Peak mid systolic strain       | − 0.225 (0.037) (n = 69) | − 0.244 (0.033) (n = 23) | 0.032                              | 0.020 (0.002, 0.039), 0.032                            | 0.019 (− 0.001, 0.040), 0.066                                                  |
| Mid S'                          | − 1.205 (0.209) (n = 69) | − 1.398 (0.237) (n = 23) | **< 0.001**                      | **0.200 (0.089, 0.311)**                               | **0.227 (0.104, 0.001)** 0.349 < 0.001                                     |
| Mid E'                          | 0.70 (0.21) (n = 69) | 0.69 (0.29) (n = 23) | 0.794                              | 0.02 (− 0.003, 0.01), 0.04                            | 0.04 (− 0.09, 0.17), 0.791 0.511                                                |
| Mid A'                          | 1.65 (0.36) (n = 68) | 2.11 (0.50) (n = 23) | **< 0.001**                       | **− 0.44 (− 0.64, − 0.45), < 0.001**                   | **− 0.45 (− 0.67, − 0.26), < 0.001**                                           |
| Peak twist (degrees)            | 10.77 (4.31) (n = 69) | 12.38 (3.74) (n = 23) | 0.113                              | − 2.026 (− 4.162, 0.110), 0.063                      | − 2.451 (− 4.823, 0.080) 0.434                                                  |
| Torsion (degrees)               | 10.94 (3.86) (n = 68) | 10.80 (4.41) (n = 23) | 0.886                              | − 0.284 (− 2.331, 1.764), 0.784                      | − 0.889 (− 3.139, 1.360), 0.434                                                |
| Native (inferoseptal) T1 = (ms) | 1156.82 (53.07)     | 1186.00 (49.30) | 0.017                              | − 30.09 (− 56.30, − 3.88), 0.025                     | − 34.78 (− 64.09, − 5.50) 0.021                                                |
| Pulse wave velocity (m/sec)     | 7.8 (2.9) (n = 73) | 7.2 (2.3) (n = 23) | 0.339                              | − 0.289 (− 1.483, 0.905), 0.632                      | − 0.443 (− 1.639, 0.753), 0.464                                                |
| Aortic distensibility           | 2.60 (1.82) (n = 75) | 3.83 (1.56) (n = 25) | **0.003**                         | − 0.340 (− 0.996, 0.316), 0.307                      | − 0.222 (− 0.936, 0.492), 0.538                                                |

Bold values represent statistical significance
Values expressed as mean (SD) unless stated otherwise

A’ late/active diastolic strain rate, E’ early diastolic strain rate, EDV end-diastolic volume, ESV end-systolic volume, LV left ventricular, S’ peak systolic strain rate

*CV risk factors: hypertension (history/anti-hypertensive agent), dyslipidaemia (history/lipid-lowering medication/TC/HDL-C ratio > 6), ever smoked, premature CVD family history. Using Holm’s method for multiple comparisons correction, threshold for statistical significance at 5% level set to p < 0.016

The reason for reduced LVMI in RA is unclear, especially given that LV mass usually increases with cardiovascular risk [36]. Indeed, the ten-year cardiovascular risk scores in this study correlated strongly with increasing LV mass (rho = 0.473 for JBS2 scores, p < 0.001). Possible causes for lower LVMI in RA patients could include physical deconditioning, myocarditis [9], microvascular dysfunction [37], or even cardiac remodelling [38] given abnormal geometry in RA has been reported previously [39]. The reduction in LVMI may also reflect the pathological processes of ‘RA-cachexia’ (loss of muscle mass with increase in fat mass) [40]. Although RA cachexia is a cytokine driven process,
studies fail to demonstrate its improvement following suppression of disease activity [40].

This study also demonstrated that traditional cardiovascular risk factors associated with surrogate measures of subclinical CVD, rather than RA specific features. The European Guidelines on CVD prevention provide clear recommendations applicable to those with RA [41], with lower cardiovascular event rates associated with improvement of cardiovascular risk factors in RA [42]; however, in practice, the management of cardiovascular risk in RA is suboptimal [43]. This should therefore become a priority for the reduction of CVD in RA.

Limitations

Although relatively large compared to previous studies, this exploratory study was not powered, however, we feel the findings are worth further consideration and validation. This cross-sectional study was also unable to quantify the burden of inflammation patients with RA were exposed to over time. The cohort had established severe disease with many requiring multiple/biological disease-modifying anti-rheumatic drugs, however, they were also in remission. In the absence of previous regular measures of disease activity/inflammation, disease duration in this cohort is the proxy measure for burden of disease. The cumulative exposure to corticosteroids (known to increase LV mass) was not quantified and it was not possible to measure the effect of DMARDs, although published data suggests DMARDs can reduce arterial stiffness and CV risk most likely through the reduction of disease activity and systemic inflammation [2].

We were surprised to see a trend for reduced native (inferoseptal) T1 in those with RA. We repeated the analysis for global T1 (average of all myocardial segments) measurements and found no such difference between the groups (1111.80 (52.35) in RA vs. 1111.47 (53.37) in controls, p = 0.978. We acknowledge the addition of post-contrast T1 measurements to derive extra-cellular volume, would have provided greater detail on myocardial tissue composition. Future research agenda.

Larger and longitudinal studies of CMR in RA are required to validate these findings, determine at which point the changes occur, and if they are amenable for improvement.

Table 4 Univariable and multivariable analysis of variables associated with CMR measured LVMI

| Variable                                | LVMI                                      |
|-----------------------------------------|-------------------------------------------|
|                                         | Univariable analysis                      |
|                                         | (number of observations = 74, unless otherwise stated) | Multivariable analysis |
|                                         | R² = 0.601, n = 68                         |
|                                         | B (95% CI)                                 | p value               |
|                                         | Correlation coefficient                    |
| Age*                                    | 0.139                                     | 0.238                  |
| Male sex*                               | 0.665                                     | <0.001                 |
| Systolic blood pressure*                | 0.344                                     | 0.003                  |
| Ever smoked*                            | 0.186                                     | 0.113                  |
| Body mass index                         | 0.005                                     | 0.964                  |
| Waist/hip circumference                 | 0.327                                     | 0.005                  |
| TC/HDL-C*                               | 0.059                                     | 0.626                  |
| HOMA-IR                                 | 0.137                                     | 0.261                  |
| RA disease duration*                    | 0.172                                     | 0.142                  |
| 3 Variable DAS28                        | 0.042                                     | 0.725                  |
| ACPA*                                   | −0.156                                    | 0.187                  |
| HAQ-DI                                  | −0.140                                    | 0.247                  |
| History of joint surgery                | 0.112                                     | 0.344                  |
| Current use of biological DMARD         | −0.008                                    | 0.949                  |

Bold values represent statistical significance

ACPA anti-citrullinated peptide antibody, CRP C-reactive protein, DAS28CRP 28-joint disease activity score, DMARD disease-modifying anti-rheumatic drug, HAQ-DI health assessment questionnaire-disability index, HOMA-IR homeostasis model of assessment of insulin resistance, LVMI LV mass index, NT-proBNP N-terminal pro-brain natriuretic peptide, TC/HDL-C total cholesterol/high-density lipoprotein cholesterol ratio

*Entered into linear regression model as associated with LV mass in the literature
†Excluding high outlier: Correlation coefficient B − 0.025 (95% CI − 2.732, 2.195) p = 0.828
with the treatment of RA in the biologic era. Further work is required to understand the underlying pathophysiology, particularly of the reduced LVMI, including any relationship with RA-cachexia. There is also a need for the development of effective cardiovascular risk reduction programs. We also acknowledge defining subclinical cardiovascular disease using CMR imaging is currently difficult given the multiple domains/measurements. A future area of focus for cross-speciality collaborations such as ours should be to define how subclinical disease is reported.

Table 5 Univariable and multivariable analysis of variables associated with CMR measured LVEF

| Variable                              | LVEF | Univariate analysis (n = 74, unless otherwise stated) | Multivariable analysis R²=0.139, n=71 |
|---------------------------------------|------|-----------------------------------------------------|-------------------------------------|
|                                       |      | Correlation coefficient | B (95% CI) p value | B (95% CI) p value |
| Age*                                  | 0.152| 0.075 (−0.039, 0.190) | 0.195 | 0.079 (−0.041, 0.200) | 0.191 |
| Male sex*                             | −0.281| −2.897 (−5.219, −0.574) | 0.015 | −3.246 (−5.629, −0.863) | 0.008 |
| Systolic blood pressure*              | 0.107| 0.025 (−0.030, 0.080) | 0.365 | 0.022 (−0.036, 0.081) | 0.452 |
| Ever smoked*                          | 0.034| 0.314 (−1.847, 2.474) | 0.773 | 0.069 (−2.048, 2.185) | 0.948 |
| Body mass index                       | 0.092| 0.129 (−0.200, 0.458) | 0.437 | – | – |
| Waist/hip circumference               | −0.022| −1.279 (15.390, 12.833) | 0.857 | – | – |
| TC/HDL-C*                             | 0.072| 0.319 (−0.746, 1.384) | 0.553 | 0.333 (−0.698, 1.363) | 0.521 |
| HOMA-IR                               | −0.008| −0.017 (−0.522, 0.489) | 0.410 | – | – |
| NT-proBNP                             | 0.064| 0.004 (−0.012, 0.020) | 0.850 | – | – |
| RA disease duration                   | −0.024| −0.011 (−0.115, 0.094) | 0.851 | – | – |
| 3 Variable DAS28                      | 0.047| 0.169 (−0.674, 1.012) | 0.690 | – | – |
| ACPA                                  | 0.020| 0.235 (−2.523, 2.994) | 0.866 | – | – |
| HAQ-DI                                | −0.050| −0.293 (−1.722, 1.136) | 0.448 | – | – |
| History of joint surgery              | −0.001| −0.014 (−2.398, 2.369) | 0.990 | – | – |
| Current use of biological-DMARD       | 0.128| 1.250 (−1.027, 3.527) | 0.277 | – | – |

Bold values represent statistical significance in multivariable analysis

ACPA anti-citrullinated peptide antibody, CRP C-reactive protein, DAS28CRP 28 joint disease activity score, DMARD disease-modifying anti-rheumatic drug, HAQ-DI health assessment questionnaire-disability index, HOMA-IR homeostasis model of assessment of insulin resistance, LVEF left ventricular ejection fraction, NT-proBNP N-terminal pro-brain natriuretic peptide, S’ peak systolic strain rate, TC/HDL-C total cholesterol/high-density lipoprotein cholesterol ratio

*Entered into linear regression model as associated with LVEF in the literature
†Excluding high outlier: Correlation coefficient 0.108 B 0.521 (95% CI −0.585, 1.627) p=0.350

Conclusions

In summary, this CMR study has demonstrated that patients with established RA and no history of CVD have evidence of reduced LV systolic function and LVMI after adjustment for traditional cardiovascular risk factors. The reduction in LVMI suggests cardiac pathology other than atherosclerosis in RA. Traditional cardiovascular risk factors appear to be key determinants of subclinical CVD in RA potentially warranting more effective cardiovascular risk reduction programs.

Acknowledgements We would like to acknowledge the LIRRM and LICAMM research nursing and administrative staff within the University of Leeds, particularly Petra Bijsterveld (senior cardiology research nurse) and Oliver Wordsworth (rheumatology research nurse), who helped conduct this study. Support was received from the Leeds NIHR Clinical Research Facility. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Funding This study was funded internally and supported by the National Institute for Health Research (NIHR) Leeds Biomedical Research Centre and NIHR Leeds Clinical Research Facility. The views expressed are those of the authors and not necessarily those of the NHS, NIHR or the Department of Health.

Compliance with ethical standards

Conflict of interest The authors declare no conflicts of interest.

Ethical approval The work within this study was approved by the Leeds West ethics committee (REC 09/H1307/98 and REC 10/H1307/103) and have therefore been performed in accordance with the ethical
standards laid down in the 1964 Declaration of Helsinki and its later amendments.

**Informed consent** All persons gave their informed consent prior to their inclusion in the study.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Innala L, Moller B, Ljung L, Magnusson S, Smedby T et al (2011) Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a 5 year prospective study. Arthritis Res Ther 13(4):R131

2. Mavrogeni S, Krikis PP, Gialafos E, Bratis K, Karabela G et al (2014) Cardiac tissue characterization and the diagnostic value of cardiovascular magnetic resonance in systemic connective tissue diseases. Arthritis Care Res 66(1):104–112. https://doi.org/10.1002/acr.22181

3. Mavrogenis S, Karabela G, Stavropoulos E, Gialafos E, Sfendouraki E et al (2013) Imaging patterns of heart failure in rheumatoid arthritis evaluated by cardiovascular magnetic resonance. Int J Cardiol 168(4):4333–4335. https://doi.org/10.1016/j.ijcard.2013.05.085

4. Ntusi NA, Piechnik SK, Francis JM, Ferreira VM, Matthews PM et al (2015) Diffuse myocardial fibrosis and inflammation in rheumatoid arthritis: insights from CMR T1 mapping. JACC Cardiovascular Imaging 8(5):526–536. https://doi.org/10.1016/j.jcmg.2014.12.025

5. Giles JT, Malayeri AA, Fernandes V, Post W, Blumenthal RS et al (2010) Left ventricular structure and function in patients with rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging. Arthritis Rheum 62(4):940–951

6. Erhayem B, DiCiarmid A, Swoboda P, Kidambi A, Ripley D et al (2015) OP0163 treatment-naïve, early rheumatoid arthritis Patients demonstrate vascular and myocardial abnormalities on cardiac MRI. Ann Rheum Dis 74(Suppl 2):130–131. https://doi.org/10.1136/annrheumdis-2015-eular.5279

7. Aslam F, Bandepalli S, Khan NA, Alam M (2013) Diastolic dysfunction in rheumatoid arthritis: a meta-analysis and systematic review. Arthritis Care Res 65(4):534–543. https://doi.org/10.1002/acr.21861

8. Kobayashi H, Kobayashi Y, Giles JT, Yoneyama K, Nakajima Y et al (2014) Tocilizumab treatment increases left ventricular ejection fraction and decreases left ventricular mass index in patients with rheumatoid arthritis without cardiac symptoms: assessed using 3.0 tesla cardiac magnetic resonance imaging. J Rheumatol 41(10):1916–1921. https://doi.org/10.3899/jrheum.131540

9. Crowson CS, Nicola PJ, Kremers HM, O’Fallon WM, Therneau TM et al (2005) How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease? Arthritis Rheum 52(10):3039–3044. https://doi.org/10.1002/art.21349

10. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324

11. Smolen JS, Breedveld FC, Eberl G, Jones I, Leeming M et al (1995) Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum 38(1):38–43

12. Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23(2):137–145

13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419

14. Alfakh K, Plein S, Thiele H, Jones T, Ridgway JP et al (2003) Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady-state free precession imaging sequences. J Magn Res Imaging 17(3):323–329. https://doi.org/10.1002/jmri.10262

15. Burns J, Sivananthan MU, Ball SG, Mackintosh AF, Mary DASG et al (2007) Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension—response. Circulation 116(17):E417–E417. https://doi.org/10.1161/Circulationaha.107.725903

16. Lee JM, Shirodaria C, Jackson CE, Robson MD, Antoniades C et al (2007) Multi-modal magnetic resonance imaging quantifies atherosclerosis and vascular dysfunction in patients with type 2 diabetes mellitus. Diab Vasc Dis Res 4(1):44–48. https://doi.org/10.3132/dvdr.2007.005

17. Messroghi DR, Bainbridge GJ, Alfakh K, Jones TR, Plein S et al (2005) Assessment of regional left ventricular function: accuracy and reproducibility of positioning standard short-axis sections in cardiac MR imaging. Radiology 235(1):229–236. https://doi.org/10.1148/radiol.2351040249

18. Messroghi DR, Greiser A, Frohlich M, Dietz R, Schulz-Menger J (2007) Optimization and validation of a fully-integrated pulse sequence for modified look-locker inversion-recovery (MOLLI) T1 mapping of the heart. J Magn Reson Imaging 26(4):1081–1086. https://doi.org/10.1002/jmri.21119

19. Messroghi DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan MU et al (2004) Modified Look-Locker inversion recovery (MOLLI) for high-resolution T-1 mapping of the heart. J Magn Reson Imaging 20(6):141–146. https://doi.org/10.1002/jmri.20110

20. Schulz-Menger J, Bluemke DA, Bremerich J, Flamm SD, Fogel MA et al (2013) Standardized image interpretation and post processing in cardiovascular magnetic resonance: society for...
cardiovascular magnetic resonance (SCMR) board of trustees task force on standardized post processing. J Cardiovasc Magn Reson 15(1):35

25. Oliver JJ, Webb DJ (2003) Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. Arterioscler Throm Vas 23(4):554–566

26. Ibrahim ESH, Johnson KR, Miller AB, Shaffer JM, White RD (2010) Measuring aortic pulse wave velocity using high-field cardiovascular magnetic resonance: comparison of techniques. J Cardiovasc Magn Reson 12(1):26

27. Ripley DP, Negrou K, Oliver JJ, Worthy G, Struthers AD et al (2015) Aortic remodelling following the treatment and regression of hypertensive left ventricular hypertrophy: a cardiovascular magnetic resonance study. Clin Exp Hypertens 37(4):308–316. https://doi.org/10.3109/10601963.2014.960974

28. Swoboda PP, Larghat A, Zaman A, Fairbairn TA, Motwani M et al (2014) Reproducibility of myocardial strain and left ventricular twist measured using complementary spatial modulation of magnetization. J Magn Reson Imaging 39(4):887–894. https://doi.org/10.1002/jmri.24223

29. Musa TA, Uddin A, Swoboda PP, Fairbairn TA, Dobson LE et al (2017) Cardiovascular magnetic resonance evaluation of symptomatic severe aortic stenosis: association of circumferential myocardial strain and mortality. J Cardiovasc Magn Reson 19(1):13. https://doi.org/10.1186/s12968-017-0329-7

30. McDiarmid AK, Broadbent DA, Higgins DM, Swoboda PP, Kidambi A et al (2015) The effect of changes to MOLLI scheme on T1 mapping and extra cellular volume calculation in healthy volunteers with 3 tesla cardiovascular magnetic resonance imaging. Quant Imaging Med Surg 5(4):503–510. https://doi.org/10.3978/j.issn.2223-4292.2015.04.07

31. Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Stat 6(2):65–70

32. Corrao S, Argano C, Pistone G, Messina S, Calvo L et al (2015) Cardiovascular magnetic resonance evaluation of systolic myocardial function in patients with rheumatoid arthritis. Ann Rheum Dis 74(2):371–376. https://doi.org/10.1136/annrheumdis-2016-209223

33. Midtbo H, Semb AG, Matre K, Kvien TK, Gerdts E (2017) Dissection in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance: are they interchangeable? Eur Heart J 21(16):1387–1396. https://doi.org/10.1053/euhj.2000.2011

34. Bellenger NG, Burgess MI, Ray SG, Lahiri A, Coats AJ et al (2000) Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J 21(16):1387–1396. https://doi.org/10.1053/euhj.2000.2011

35. Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ (2000) Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2(4):271–278

36. Armstrong AC, Gidding S, Gjesdal O, Wu C, Bluemke DA et al (2012) LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice. JACC Cardiovasc Imaging 5(8):837–848. https://doi.org/10.1016/j.jcmgi.2012.06.003

37. Ciftci O, Yilmaz S, Topcu S, Caliskan M, Gullu H et al (2008) Impaired coronary microvascular function and increased intima-media thickness in rheumatoid arthritis. Atherosclerosis 198(2):332–337. https://doi.org/10.1016/j.atherosclerosis.2007.11.013

38. Cohn JN, Ferrari R, Sharpe N (2000) Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 35(3):569–582

39. Myasoedova E, Davis JM 3rd, Crowson CS, Roger VL, Karon BL et al (2013) Brief report: rheumatoid arthritis is associated with left ventricular concentric remodeling: results of a population-based cross-sectional study. Arthritis Rheum 65(7):1713–1718. https://doi.org/10.1002/art.37949

40. Summers GD, Deighton CM, Rennie MJ, Booth AH (2008) Rheumatoid cachexia: a clinical perspective. Rheumatology 47(8):1124–1131. https://doi.org/10.1093/rheumatology/ken146

41. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C et al (2016) 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 37(29):2315–2381. https://doi.org/10.1093/eurheartj/ehw106

42. Kitas GD, Nightingale P, Armitage J, Sattar N, Belch JFF et al (2015) Trial of atorvastatin for the primary prevention of cardiovascular events in patients with RA (TRACE RA): a randomized trial in 2986 RA patients (094). Rheumatology 54(suppl 1):i87. https://doi.org/10.1093/rheumatology/kev088.094

43. Scott IC, Ibrahim F, Johnson D, Scott DL, Kingsley GH (2012) Current limitations in the management of cardiovascular risk in rheumatoid arthritis. Clin Exp Rheumatol 30(2):228–232

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.